• Imaging of Intracerebral Inflammation in MS

  NCT02305264

  CompletedInterventionalNot ApplicableUpdated Sep 16, 2022
• PET Imaging of Neuroinflammation in Neurodegenerative Diseases Via a Novel Translocator Protein (TSPO) Radioligand

  NCT03958630

  TerminatedInterventionalPhase 1Updated May 1, 2024
• Remyelination in Multiple Sclerosis: a PET-MR Longitudinal Study Investigating Individual Profiles of Myelin Repair and the Contribution of Neuroinflammation

  NCT05147532

  Unknown statusInterventionalNot ApplicableUpdated Sep 13, 2023
• Measure of Microglial Activation in the Brain of Parkinson Disease Patients With PET

  NCT02319382

  Unknown statusInterventionalNot ApplicableUpdated Jul 14, 2015
• TSPO-PET/MRI in Surveillance of Neuroinflammation in the Central Nervous System

  NCT06467773

  RecruitingObservationalUpdated Apr 8, 2025
• PET Imaging of the Translocator Proteine Ligands (TSPO) With [18 F] DPA-714 Biomarker of NeuroInflammation in Cognitive Decline (NIDECO)

  NCT02062099

  CompletedInterventionalPhase 1Updated Sep 14, 2022

ClinicalTrials.gov ID

NCT06280742

Lead Sponsor

Assistance Publique - Hôpitaux de ParisOTHER

Overall Status

Recruiting

Study Type

Interventional

Phase

Not Applicable

Enrollment

41Estimated

Last Update Posted

Mar 6, 2026Actual

Start Date

Dec 16, 2025Actual

Primary Completion Date

Dec 2028Estimated

Completion Date

Dec 2028Estimated

Official Title

Study of Neuroinflammation in Multiple Sclerosis by PET-MRI Imaging Using the Radiotracer ([18F]-DPA-714) : a Multicentre Cohort Study

Brief Summary

The Service Hospitalier Frédéric-Joliot (SHFJ) and Paris Brain Institute (ICM) groups have identified [18F]-DPA-714 as a promising second-generation TSPO tracer, a macromolecule overexpressed in neuroinflammatory conditions, for PET imaging. They have also developed a non-invasive quantification methodology, enabling the generation of individual neuroinflammation maps in MS patients. Recent findings from [18F]-DPA-714 PET imaging in MS patients revealed that most of the white matter lesions contained a smoldering component, even when considered inactive on MRI, and that their neuroinflammatory profiles were associated with longitudinal disability worsening. The Inflanet project aims to leverage a unique consortium comprising French radiochemists, radiopharmacists, nuclear medicine/neuroimaging experts, and MS neurologists to establish the first national network dedicated to [18F]-DPA-714 PET imaging in MS, so far limited to monocentric studies.

The objectives of the INFLANET project are (1) to conduct the first multicenter study assessing neuroinflammation in patients with active MS using [18F]DPA-714 PET tracer, and (2) to establish a methodology suitable for the quantification of multicenter PET data obtained with [18F]DPA-714. The INFLANET initiative aims to disseminate TSPO PET within the French MS research community, thereby opening the unique perspective of future large-scale, multicenter studies. These endeavors are expected to enhance our capacity to predict diseases, stratify patients, and assess new therapeutic interventions.

Detailed Description

INFLANET is a multicentric, prospective, non-randomized, non-blinded, interventional study.The study will include a total of 41 participants, with 18 individuals diagnosed with multiple sclerosis (MS) distributed across three sites (6 patients per site: Paris, Lyon, Rennes). Additionally, there will be 23 healthy volunteers (HV), with 20 HV allocated to the Lyon and Rennes sites (10 HV per site) and 3 HV for the Paris site.

The study involves several clinical visits, with two visits for patients (Screening V0 and Baseline V1), two visits for 20 healthy volunteers (Screening V0 and Baseline V1), and three visits for three healthy volunteers (Screening V0, Baseline V1 - Test, and V1' - Retest, in Paris site). Various evaluations are integrated into the study, including neurological assessments at the screening visit, neuropsychological assessments at the baseline visit, 18F-DPA714 PET-MR or PET + MRI (n=1 for 20 HV and 18 subjetcs with MS; n=2 for 3 HV) at V1 and V1', and blood sampling at the screening visit to confirm TSPO eligibility.

The PET-MR procedure involves TSPO PET using [18F]-DPA-714 in conjunction with 3T MRI for both MS patients and healthy volunteers. Gadoteric acid is administered for MS patients only as part of the imaging.

• Multiple Sclerosis

• PET-MRI with [18F]-DPA-714

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

Yes

Eligibility Criteria

Inclusion Criteria:

RRMS patients:

• Age between 18 and 55 years old
• RRMS according to the 2017 Mc Donald criteria
• At least 9 supra-tentorial white matter lesions on T2/FLAIR MRI
• Last treatment with methylprednisolone should have been performed at least 1 month before PET examinations
• No current disease modifying therapy
• Indication for a highly active disease modifying treatment: Natalizumab, anti CD20 antibody, Alemtuzumab, sphingosine-1 phosphate modulator, or cladribine. This will consist either as patients with an active form of relapsing MS or patients who have experienced two relapses during the previous year
• Affiliation to a social security scheme or beneficiary of such a scheme (except "Aide Médicale d'Etat")

Healthy Volunteers:

• Age between 18 and 55 years old
• Without any evolutive pathology
• Able to understand the study objectives and procedures
• Affiliation to a social security scheme or beneficiary of such a scheme (except "Aide Médicale d'Etat")

Exclusion Criteria:

For all participants:

• Any reasons, which does not allow to perform MRI, including claustrophobia, the implant of a pace-maker or the presence of an intra-ocular foreign body, (a contra-indication questionnaire will be filled in beforehand)
• Realization of any test using radioactivity within the last 12 months
• Low Affinity Binding profile (analyse of TSPO polymorphism done at screening visit)
• Pregnancy, breast-feeding, lack of efficient contraception for women of childbearing potential
• Current symptoms of severe or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary or cardiac disease, or any other chronic neurological diseases
• Unwillingness to be informed in case of unexpected MRI abnormality (with a significant medical anomaly)
• Patient under legal protection
• Participation in another interventional study or being in the exclusion period at the end of a previous study

RRMS patients:

• Hypersensitivity to gadoteric acid
• Meglumine or any drug containing gadolinium
• Severe renal insufficiency (creatinine clearance < 60mL/min and GFR <30ml / min / 1.73m2).

Primary Purpose

Other

Allocation

Non-Randomized

Interventional Model

Parallel Assignment

Masking

None (Open Label)

Lead Sponsor

Assistance Publique - Hôpitaux de ParisOTHER

francoise.durand-dubief@chu-lyon.fr04 72 35 75 22 ext. +33